Search clinical trials for: Enfuvirtide

Total 39 results

University of California, San Francisco
Universitywide AIDS Research Program

Completed

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

HIV Infections

United States
Canadian Immunodeficiency Research Collaborative
Hoffmann-La Roche

Completed

Fuzeon Viral Decay Pilot Study

HIV-1

Canada
Hoffmann-La Roche

Completed

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

HIV Infections

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection

HIV Infections

Bulgaria
Hoffmann-La Roche
Trimeris

Completed

BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection

HIV Infections

United States, Puerto Rico
Hoffmann-La Roche
Trimeris

Completed

WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.

HIV Infections

United States
Hoffmann-La Roche

Terminated

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

HIV Infection

United States
Hoffmann-La Roche
Trimeris

Completed

A Study Comparing the Efficacy and Safety of Once-Daily Fuzeon (Enfuvirtide) Dosing Versus the Currently Recommended Twice-Daily Dosing in Human Immunodeficiency Virus-Type 1 (HIV-1) Infected Patients

HIV Infections

United States, Canada, Puerto Rico
Hoffmann-La Roche
Trimeris

Completed

BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.

HIV Infections

United States, Australia
Hoffmann-La Roche

Completed

INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.

HIV Infections

France
Hoffmann-La Roche

Withdrawn

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

HIV Infections

Australia
National Institute of Allergy and Infectious Diseases...

Unknown

Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection

HIV Infections

United States
Hoffmann-La Roche
Trimeris

Terminated

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (AMICI)

HIV Infections

United States, Puerto Rico
Institute for Interdisciplinary Infectiology
Hoffmann-La Roche

Unknown

Cohort Study for Patients Using Fuzeon (Enfuvirtide)

HIV Infections | Antiretroviral Treatment

Germany
Tibotec Pharmaceuticals, Ireland

Completed

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Human Immunodeficiency Virus Type 1
Hoffmann-La Roche
Trimeris

Completed

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

HIV Infections

United States, Canada
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

HIV Infections

United States, Puerto Rico
Trimeris

Completed

A Study of T-20 in HIV-Positive Adults

HIV Infections

United States
Hoffmann-La Roche
Trimeris

Completed

T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs

HIV Infections

Switzerland, Spain, United Kingdom, Germany, Belgium, Australia, Sweden, Italy, Netherlands
National Institute of Allergy and Infectious Diseases...

Completed

Adding New Drugs for HIV Infected Patients Failing Current Therapy

HIV Infections

United States, Puerto Rico
Hoffmann-La Roche
Trimeris

Completed

T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents

HIV Infections

United States
Trimeris
Hoffmann-La Roche

Completed

Study of Enfuvirtide in HIV-Positive Subjects

HIV Infections | AIDS

United States
Hoffmann-La Roche

Completed

A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection

HIV Infections

Thailand
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience (INTENSE)

HIV Infections

France, Germany, Spain, Italy, United States, Switzerland, Netherlands, Mexico, Canada, Israel
Hospital Clinic of Barcelona
Hoffmann-La Roche

Completed

Metabolic Effects of Enfuvirtide in Healthy Volunteers

HIV Infections

Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

HIV

United States
Hoffmann-La Roche

Completed

Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

HIV Infections

France
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France
Boehringer Ingelheim

Terminated

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

HIV Infections

United States, Argentina, Brazil, Canada, Germany, Italy, Spain
French National Agency for Research on AIDS and...
Gilead Sciences; Hoffmann-La Roche

Completed

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

HIV Infections | Leukoencephalopathy, Progressive Multifocal

France
French National Agency for Research on AIDS and...
Gilead Sciences; Hoffmann-La Roche

Completed

Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)

HIV Infections | AIDS

France
University of North Carolina, Chapel Hill

Terminated

Study of Valproic Acid to Treat HIV Infected Adults

HIV Infections

United States
Kirby Institute
National Heart, Lung, and Blood Institute (NHLBI); St Vincent's Hospital, Sydney

Completed

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Cardiovascular Disease | HIV-Associated Lipodystrophy Syndrome

Australia
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

HIV Infections

United States, Puerto Rico
National Institute of Allergy and Infectious Diseases...
AIDS Clinical Trials Group

Completed

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

HIV Infections

United States, Puerto Rico
University of Maryland, Baltimore

Completed

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

HIV Infections

United States
Hoffmann-La Roche
Trimeris

Completed

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

HIV Infections

United States
University Hospital, Tours
University Hospital, Rouen; Central Hospital, Nancy, France; Poitiers University... and other collaborators

Completed

Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (TRULIGHT)

HIV

France

3

Subscribe